Skip to main content
Conferences and Meetings 901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster III

901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster III

Short name: updated-901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster III-2025 Annual Meeting Poster Bundle Health Services & Outcomes Research
Course start date: 02/05/2026

Sections

General
0 activities

Improving bone marrow biopsy core length and aspirate adequacy through implementation of a powered device A single institution quality improvement initiative
An implementation science approach to optimize adoption of hematopoietic cell transplant survivorship care plans
Systematic review on the diagnostic evaluation of pediatric evans syndrome
Impact of iron deficiency anemia on outcomes in postpartum hemorrhage Insights from a national inpatient sample analysis
Effect of duffy status on patients with breast cancer receiving cyclin dependent kinase 4 6 inhibitors
Lower dose emicizumab prophylaxis in children with hemophilia A Real world outcomes hemostatic profiles and cost effectiveness from a resource limited setting
Direct oral anticoagulation management to address primary and secondary adherence in atrial fibrillation
Toxicity and efficacy profile of cardioprotective vs conventional doxorubicin A meta analysis
Construction and validation of a prediction model for extracorporeal circuit clotting risk during regional citrate anticoagulation in continuous renal replacement therapy for critically ill patients with hematological disorders
High versus low cost intravenous iron in Medicare Utilization patterns of iron infusions in traditional fee for service Medicare and Medicare advantage for iron deficiency anemia
Prospective observational cohort study to collect granular social determinants of health data for hematopoietic cell transplant patients
primary prophylaxis with direct oral anticoagulants DOACs for transwomen taking estrogen is not cost effective
Irregulab Automated interpretation of irregular antibody panels

Vimeo Vimeo
13